Designed proteins assemble antibodies into modular nanocages.

Divine, Robby; Dang, Ha V; Ueda, George; Fallas, Jorge A; Vulovic, Ivan; Sheffler, William; Saini, Shally; Zhao, Yan Ting; Raj, Infencia Xavier; Morawski, Peter A; Jennewein, Madeleine F; Homad, Leah J; Wan, Yu-Hsin; Tooley, Marti R; Seeger, Franziska; Etemadi, Ali; Fahning, Mitchell L; Lazarovits, James; Roederer, Alex; Walls, Alexandra C; Stewart, Lance; Mazloomi, Mohammadali; King, Neil P; Campbell, Daniel J; McGuire, Andrew T; Stamatatos, Leonidas; Ruohola-Baker, Hannele; Mathieu, Julie; Veesler, David; Baker, David

Multivalent display of receptor-engaging antibodies or ligands can enhance their activity. Instead of achieving multivalency by attachment to preexisting scaffolds, here we unite form and function by the computational design of nanocages in which one structural component is an antibody or Fc-ligand fusion and the second is a designed antibody-binding homo-oligomer that drives nanocage assembly. Structures of eight nanocages determined by electron microscopy spanning dihedral, tetrahedral, octahedral, and icosahedral architectures with 2, 6, 12, and 30 antibodies per nanocage, respectively, closely match the corresponding computational models. Antibody nanocages targeting cell surface receptors enhance signaling compared with free antibodies or Fc-fusions in death receptor 5 (DR5)-mediated apoptosis, angiopoietin-1 receptor (Tie2)-mediated angiogenesis, CD40 activation, and T cell proliferation. Nanocage assembly also increases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus neutralization by α-SARS-CoV-2 monoclonal antibodies and Fc-angiotensin-converting enzyme 2 (ACE2) fusion proteins.